Information Provided By: 
Fly News Breaks for June 11, 2018
EGRX
Jun 11, 2018 | 06:22 EDT
Mizuho analyst Irina Koffler upgraded Eagle Pharmaceuticals to Neutral and raised her price target for the shares to $62 from $54. The analyst cites the positive legal decision on Bendeka orphan drug exclusivity for the upgrade, but she remains cautious about the outcome of the Ryanodex EHS trial. Koffler learned Eagle won its orphan drug dispute with the FDA, and thinks the company gained seven years of retroactive market exclusivity for Bendeka. She believes the win should obstruct Treanda powder generics from entering the market until late 2022.
News For EGRX From the Last 2 Days
There are no results for your query EGRX
